Drug Profile
ITI 333
Alternative Names: ITI-333Latest Information Update: 16 Apr 2024
Price :
$50
*
At a glance
- Originator Intra-Cellular Therapies
- Class Antidepressants; Antipsychotics; Anxiolytics; Drug withdrawal therapies; Mood stabilisers; Opioid analgesics; Small molecules
- Mechanism of Action Dopamine D1 receptor antagonists; Opioid receptor agonists; Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Substance-related disorders
- Preclinical Mood disorders; Pain
- No development reported Anxiety disorders
Most Recent Events
- 31 Dec 2023 Intra-Cellular Therapies has patent protection for ITI 333 in the US, prior to December 2023
- 31 Dec 2023 Intra-Cellular Therapies has patents pending for ITI 333 in USA and multiple countries, prior to December 2023
- 29 Mar 2023 Intra-Cellular Therapeutics has patent pending for ITI 333 in multiple countries